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356 The Journal of Thoracic and Cardbjectives: Chemotherapeutic agents sensitize cancer cells to Apo2 ligand/tumor
ecrosis factor–related apoptosis-inducing ligand (Apo2L/TRAIL) via recruitment
f the mitochondria-dependent activation of caspase and induction of apoptosis.
his study was designed to evaluate whether gossypol, a phytochemical compound
ith BH3-mimetic property that functions as an inhibitor of Bcl2/BclXL, would
ensitize cultured thoracic cancer cells to this death-inducing ligand.
ethods: Cancer cell lines from the lung (H460, H322), the esophagus (TE2,
E12), and the pleura (H290, H211) or primary normal cells were treated with
ossypolApo2L/TRAIL combinations. Cell viability and apoptosis were evalu-
ted by (4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and
erminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL)
ssays, respectively. Caspase 9 and 3 specific proteolytic activity in combination-
reated cells was determined by fluorometric enzymatic assay.
esults: Gossypol, selectively cytotoxic to cancer cells and not primary normal cells,
ignificantly sensitized thoracic cancer cells to Apo2L/TRAIL as indicated by 1.5- to more
han 10-fold reduction of Apo2L/TRAIL 50% inhibitory concentration values in cells treated
ith gossypolApo2L/TRAIL combinations. Whereas less than 20% of cancer cells ex-
osed to either gossypol (5 mol/L) or Apo2L/TRAIL (20 ng/mL) were dead, more than
0% of cells treated with the drug combinations were apoptotic. Combination-induced
ytotoxicity and apoptosis was completely abrogated either by overexpression of Bcl2 or by
he selective caspase 9 inhibitor. This combination was not toxic to normal cells.
onclusion: Gossypol profoundly sensitizes thoracic cancer cells to the cytotoxic
ffect of Apo2L/TRAIL via activation of the mitochondria-dependent death signal-
ng pathway. This study provides evidence for the profound anticancer activity of
his drug combination and should be further evaluated as a novel targeted molecular
herapeutic for thoracic cancers.
etter understanding of the molecular basis of carcinogenesis and elucidation
of signal transduction pathways regulating cell growth and death in normal
cells and their roles in the process of malignant transformation offers greatpportunities for the development of novel molecularly targeted anticancer therapy.
iovascular Surgery ● December 2006
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G
TSithin this context, therapeutic strategies aiming at direct
nduction of cell death by activation of the TRAIL receptor-
ediated signal transduction pathways using the recombi-
ant protein Apo2L/TRAIL (the Zn-coordinated ho-
otrimer of the extracellular domain of TRAIL)1 or the
uman agonistic anti-DR4 monoclonal antibodies2 have at-
racted a great deal of attention for clinical development, as
hese biologics are selectively cytotoxic to cancer cells.1-4 In
act, they are currently being tested in phase 1 clinical trials.
inding of Apo2L/TRAIL to its cognate functional recep-
ors DR4 and/or DR5 activates the apical caspases 8 and 10,
hich either directly (type I pathway) or indirectly, via the
itochondria-dependent death-signaling cascade (type II
athway), activate the downstream executioner caspases 3,
, and 7 to mediate apoptotic cell death.5
Despite expressing adequate levels of functional recep-
ors DR4/DR5 for Apo2L/TRAIL, significant percentages
f cancer cells exhibit resistance to the cytotoxic effect of
his ligand in vitro. The molecular basis of this phenomenon
s complex and yet to be fully elucidated.6 It is well de-
cribed that exposure of Apo2L/TRAIL-refractory cancer
ells to standard cytotoxic chemotherapeutic agents such
s cisplatin and paclitaxel or to experimental targeted
nticancer drugs like the histone deacetylase inhibitors
such as depsipeptide or valproic acid) profoundly sensitizes
hese cells to this death-inducing ligand.7-9 Our labora-
ory,7,8 as well as others,9,10 has demonstrated that chemo-
herapeutic drugs sensitize cancer cells to Apo2L/TRAIL
ia recruitment of the mitochondria-dependent caspase ac-
ivation cascade. As such, the next logical step in the de-
elopment of efficient TRAIL-based combination therapy
or cancer is to directly target the mitochondria to stimulate
ts apoptosis-inducing property. The apoptogenicity of the
itochondria is tightly regulated by members of the Bcl2
uperfamily, which respond to various intrinsic and extrin-
ic death-promoting stimuli and ultimately decide the fate of
he affected cells.11 Suppression of antiapoptotic protein
xpression by antisense or small interfering RNA tech-
iques has been shown to sensitize cancer cells to TRAIL.12
owever, this approach, while valuable in providing proof
f concept, has limited clinical application, mainly because
Abbreviations and Acronyms
IC50  inhibitory concentration of 50%
MTT  (4,5-dimethylthiazo-2-yl)-2,5-diphenyl
tetrazolium bromide
TNF  tumor necrosis factor
TRAIL  tumor necrosis factor–related apoptosis-
inducing ligand
TUNEL terminal deoxynucleotidyltransferase–
mediated dUTP nick-end labelingf the redundancy of the Bcl2 superfamily antiapoptotic A
The Journal of Thoracicembers, the long half-life of Bcl2/BclXL proteins, and the
nefficient delivery of ribonucleic acid sequences to every
ancer cells in vivo. The antiapoptotic proteins Bcl2 or
clXL sequester the proapoptotic proteins Bad, Bid, Bim,
ax, and Bak by selective interaction between the BH3
omains of these proteins with their own BH3-binding
ockets to prevent their translocation to the mitochondria,
here they perform their death-inducing function.13 Intense
esearch and development of small molecule inhibitors of
cl2/BclXL have identified multiple compounds that can
nteract with the BH3-binding pockets of these proteins to
nhibit their antiapoptotic function.14 These drugs are com-
only referred to as BH3 mimetics.
Gossypol, a phytochemical found in cottonseed oil, was
nitially developed as an antifertility agent and subse-
uently recognized to have anticancer property15 (and refs
herein). This compound was tested in many small phase 1
linical trials.16 Gossypol, furthermore, was identified to be
BH3 mimetic by computer-assisted molecular modeling,
y nuclear magnetic resonance imaging study, and also by
uorescence-polarization assay.17 We hypothesize that gos-
ypol, via its Bcl2/BclXL inhibitory activity as a BH3
imetic, synergistically interacts with Apo2L/TRAIL to
ediate profound cytotoxicity and apoptosis of cultured
horacic cancer cells (cancer cell lines derived from primary
umors of the lung, the esophagus, or the pleura) in vitro.
aterials and Methods
ell Lines and Reagents
ultured non–small cell lung cancer cells H460 and H322, esoph-
geal cancer cells TE2 and TE12, and malignant pleural mesothe-
ioma H211 and H290 were maintained in RPMI 1640 cultured
edium supplemented with fetal calf serum (10% v/v), L-glutamine
1 mmol/L), streptomycin (100 g/mL), and penicillin (100 U/mL).
ormal human primary fibroblast and normal human bronchial
pithelia were purchased from Cambrex (Walkervile, Md) and
rown in their special culture media as per instructions of the
endor. Apo2L/TRAIL was obtained from Genentech Inc (South
an Francisco, Calif) via a Cooperative Research and Develop-
ent Agreement. Bcl2– overexpressing stable transfectants of
E2 (TE2Bcl2), TE12 (TE12Bcl2) cells, as well as their respec-
ive vector controls, were created and characterized as previously
escribed.8 Selective caspase 9 inhibitor z-LEHD-fmk was pur-
hased from Calbiochem (San Diego, Calif). Gossypol was ob-
ained from Sigma-Aldrich (St Louis, Mo), dissolved in dimeth-
lsulfoxide (25 mmol/L stock), divided into aliquots, and stored in
20°C. Fresh drug was used for each experiment to avoid repeated
reeze-thaws.
ytotoxicity and Apoptosis Assays
ells were seeded in 96-well microtiter plates at predetermined
lating densities appropriate for each cell line (1.0 to 2.0  104
ells/well) to achieve 80% confluence at the time cells were to be
reated with Apo2L/TRAIL. After an overnight incubation, cells
ere treated with either gossypol (2.5, 5.0, or 10.0 mol/L) or
po2L/TRAIL (5 to 100 ng/mL) or 1-hour pretreatment with
and Cardiovascular Surgery ● Volume 132, Number 6 1357
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G
TSossypol followed by addition of Apo2L/TRAIL (as 20 L of 10X
tock) for a total of 200 L per well. Cell viability after treatment
ith Apo2L/TRAIL alone or with gossypolApo2L/TRAIL com-
inations was calculated as percentage of untreated controls or of
ossypol-treated controls (to normalize for growth-inhibitory ef-
ect of gossypol, which ranged from 20% to 50% depending on the
uration of exposure to this drug), respectively. The Apo2L/
RAIL 50% inhibitory concentration (IC50) values were estimated
rom respective dose-response curves. Apoptosis after treatments
ith Apo2L/TRAIL (20 ng/mL) alone or in combination with
ossypol (5.0 mol/L or 10.0 mol/L) was determined by the
UNEL*-based ApoBrdU assay (both from BD-Pharmigen, Tor-
ence, Calif).
aspase Activity Assay
pecific enzymatic activity of caspases 9 and 3 at intervals after
he onset of treatment with Apo2L/TRAIL (20 ng/mL) with or
ithout gossypol (5 mol/L) in TE2, TE12, and H460 cells was
easured by enzymatic assays using fluorochrome-labeled sub-
trates (R&D Systems, Inc, Minneapolis, Minn). The specific
aspase activity, normalized for total proteins of cell lysates (BCA
echnique; Pierce Biotechnology, Rockford, Ill), was then ex-
ressed as fold of the baseline caspase activity of untreated control
ells.
tatisical Analysis
xperiments were performed in quadruplicates unless otherwise
ndicated. Supra-additive cytotoxicity or apoptosis is defined as the
ytotoxicity or apoptosis induced by the drug combinations that is,
y statistical analysis, significantly greater than the sum of cyto-
oxicity or apoptosis induced by individual drug treatment. Results
ere presented as means  standard errors of the means. The
tudent t test was performed when indicated.
esults
ntiproliferative Effect of Gossypol on Thoracic
ancer Cells
ontinuous exposure of 6 cultured cancer cells to gossypol
or 24 hours resulted in a significant dose-dependent reduc-
ion of cell proliferation as determined by the MTT† at 36
ours after the onset of drug treatment (Figure 1). The
iability of primary normal cells, on the other hand, was not
ignificantly affected by gossypol. Gossypol induced mild
ell cycle arrest at G1/S checkpoint in TE2, TE12, and
322 cells but not in H460, H211, or H290 cells (data not
hown). Moreover, gossypol mediated apoptosis of thoracic
ancer cells, the magnitude of which was clearly dependent
n the drug concentrations and the duration of drug expo-
ure (Figure E1).
TUNEL  terminal deoxynucleotidyltransferase–mediated dUTP nick-end
abeling.hMTT  (4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium bromide.
358 The Journal of Thoracic and Cardiovascular Surgery ● Decupra-additive Enhancement of Cytotoxicity by the
ossypolApo2L/TRAIL Combination
he intrinsic sensitivity to Apo2L/TRAIL varies signifi-
antly between cultured thoracic cancer cells lines, with
460, H322, and H290 being more susceptible to this
eath-inducing ligand (Apo2L/TRAIL IC50 values of 50 
, 40  2, and 53  3 ng/mL respectively) while TE2,
E12, and H211 are Apo2L/TRAIL-resistant cells (Apo2L/
RAIL IC50 100 ng/mL). All of the cancer cell lines used
n this study are type II cells.7,8 Concurrent treatment of
ultured thoracic cancer cells to gossypol (2.5-10.0 mol/L)
nd Apo2L/TRAIL (5-100 ng/mL) resulted in significant en-
ancement of Apo2L/TRAIL-mediated cytotoxicity. Gossy-
ol alone, at the treatment conditions used, mediated a cell
ine–dependent mild-to-moderate reduction of cell viability
20%-50%). The gossypol-mediated sensitization of cancer
ells to Apo2L/TRAIL was most easily appreciated when
he growth-inhibitory effect of the gossypolApo2L/TRAIL
ombinations was normalized for the gossypol-mediated
ytotoxicity, as presented in the respective dose-response
urves shown in Figure 2A for TE2, H460, and H211 cells.
ith Apo2L/TRAIL IC50 values used as indicators of cel-
ular sensitivity to this ligand, it was apparent that there was
.5- to greater than 10-fold reduction of Apo2L/TRAIL IC50
alues in gossypol-treated cells in a dose-dependent manner
Figure 2B). This effect was observed in all cultured tho-
acic cancer cells regardless of their intrinsic sensitivity to
po2L/TRAIL and particularly most pronounced in Apo2L/
RAIL-resistant TE2, TE12, and H211 cell lines. Compa-
able gossypol-mediated enhancement of Apo2L/TRAIL
ensitivity was observed in cells treated with either 12 or 24
igure 1. The effect of gossypol on the viability of thoracic
ancer cells and primary normal cells. Cells were treated with
ossypol for 24 hours and cell viability was determined by MTT
ssay at 36 hours after the onset of drug treatment. Data are
resented as means SEM of 4 independent experiments. NHBE,
ormal human bronchial epithelia; NHEK, normal human epider-
al keratinocyte; micM, micromoles per liter.ours of gossypolApo2L/TRAIL, with no further reduc-
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G
TSion of Apo2L/TRAIL IC50 after 36 hours of exposure to the
rug combination except in H211 cells (Figure E2).
hereas gossypol (5 mol/L) alone or Apo2L/TRAIL (20
g/mL) alone induced less than 20% apoptosis in represen-
ative H460, TE12, and H211 cancer cells, massive supra-
dditive induction of apoptosis of more than 90% was
igure 2B. Apo2L /TRAIL IC50 values of cultured cancer cells
reated with either Apo2L/TRAIL alone or gossypolApo2L/TRAIL
ombinations. These values were estimated from the respective
ose-response curves and used as indicators of cellular sensi-
ivity to Apo2L/TRAIL. Data are presented as means  SEM of 4
ndependent experiments; #P < .0001 and P < .01 versus
po2L/TRAIL alone by analysis of variance and Bonferroni pair-
ise analysis. micM, Micromoles per liter.bserved in combination-treated cells (Figure 3). Most im- c
The Journal of Thoracicortant, neither Apo2L/TRAIL alone nor gossypolApo2L/
RAIL combination induced apoptosis of primary human
broblasts and normal human bronchial epithelia (Figures
A and 3).
itochondria-dependent Death Signaling Cascade
lays Important Role in Enhanced Cytotoxicity by
ossypolApo2L/TRAIL
s gossypol is a BH3-mimetic drug, it most likely sensitizes
ultured thoracic cancer cells to Apo2L/TRAIL via activa-
ion of mitochondria and recruitment of the type II death
ignaling pathway. Time-course evaluation of caspase acti-
ation in TE12 cells treated with gossypol, Apo2L/TRAIL,
r gossypolApo2L/TRAIL combination indicated signif-
cant supra-additive enhancement of the specific proteo-
ytic activity of caspase 9 (apical caspase of the mito-
hondria-mediated caspase activation cascade) and the
ownstream executioner caspase 3 (Figure E3). Such
aspase activation directly contributed to Apo2L/TRAIL-
r gossypolApo2L/TRAIL-mediated cytotoxicity and
poptosis, as these were significantly abrogated by either the
eneral caspase inhibitor z-VAD-fmk or the caspase 9 in-
ibitor z-LEHD-fmk (Figure 4 and Figure E4). To further
onfirm the involvement of the mitochondria-mediated
type II) pathway in this process, we similarly treated Bcl2-
verexpressing stable transfectants TE2Bcl2 and TE12Bcl2
ells with Apo2L/TRAIL or gossypolApo2L/TRAIL
ombinations. Bcl2 overexpression completely protected
E2 or TE12 cells from Apo2L/TRAIL-mediated cytotox-
city (as in TE12 cells) and gossyplApo2L/TRAIL-mediated
Figure 2A. Gossypol sensitizes cancer
cells but not primary normal cells to
Apo2L/TRAIL-mediated cytotoxicity. Cells
were treated with Apo2L/TRAIL, gossy-
pol, or gossypolApo2L/TRAIL for 24
hours, and cell viability was assessed
by MTT at 36 hours. Data are presented
as means  SEM of 4 independent ex-
periments. NHBE, Normal human bron-
chial epithelia; micM, micromoles per
liter.ytotoxicity (in both TE2 and TE12 cells) (Figure 5).
and Cardiovascular Surgery ● Volume 132, Number 6 1359
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1
G
TS iscussion
he intrinsic sensitivity of cancer cells to TRAIL can be
nhanced by treating them with standard cytotoxic chemo-
herapeutics or with investigational drugs or gamma radia-
ion.18 The molecular basis of such enhancement effect is
omplex, cell dependent, and not completely elucidated.
everal possibilities have been postulated as the basis of
hemotherapy-induced potentiation of TRAIL cytotoxicity:
igure 3. Profound and supra-additive induction of apoptosis
y the gossypolApo2L/TRAIL combinations in representative
ancer cell lines H460, H211, and TE12. This combination does
ot induce apoptosis in primary normal cells. Data are pre-
ented as means  SEM of 4 independent experiments. G,
ossypol; NHBE, Normal human bronchial epithelia; TUNEL,
erminal deoxynucleotidyltransferase–mediated dUTP nick-
nd labeling; micM, micromoles per liter.360 The Journal of Thoracic and Cardiovascular Surgery ● Decpregulation of receptor expression, elevation of TRAIL-
nitiated signal transduction through the receptor complex
nd/or the intracellular pathways, and downregulation of
atural inhibitor proteins of the caspase cascade after treat-
ent of cancer cells with sensitizers. Whereas the molecular
asis of enhanced TRAIL cytotoxicity by these combina-
ions is diverse, functional and/or phenotypic modulation of
he mitochondria-regulated caspase-activation cascade lead-
ng to amplification of the Apo2L/TRAIL-induced apop-
osis appears to be the common theme. Our current working
odel of chemotherapy-induced sensitization of cancer cells
o Apo2L/TRAIL is as follows: Apo2L/TRAIL engagement
f its functional receptors DR4/DR5, via the formation of
he death-induced signaling complex, results in an initial
inute activation of caspase 8, which activates the mito-
hondria via cleavage of BID to form tBID. In sensitive type
I cells, this would be adequate to engage the mitochondrial
rm of the caspase activation cascade and the amplification
eedback loop to potentiate caspase 8 activation. In resistant
ells, the chemosensitizer “primes” the mitochondria via
henotypic or functional alteration of proapoptotic and an-
iapoptotic proteins of the Bcl2 superfamily to make the
itochondria more susceptible to tBID and thus effectively
ngage the mitochondria-dependent caspase activation path-
ay.7,8 Proofs of principle of such model have been dem-
nstrated by sensitization of cancer cells to TRAIL by
argeting the mitochondria using BclXL small interfering
NA12 or the mitochondriotropic cytotoxic drug betulinic
cid.19 The gossypolApo2L/TRAIL drug combination
as thus designed on the basis of the observation that
Figure 4. Significant reduction of gos-
sypolApo2L/TRAIL-mediated apoptosis
by the general caspase inhibitor Z-VAD-
fmk or the caspase 9 inhibitor Z-LEHD-
fmk in H211 and TE12 cells. Representa-
tive data of 3 independent experiments
with similar results are shown.ember 2006
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G
TSitochondria are essential for the chemotherapy-induced
otentiation of Apo2L/TRAIL cytotoxicity and the hypoth-
sis that functional inhibition of Bcl2/BclXL using BH3-
imetic drugs like gossypol would sensitize cancer cells to
his death-inducing ligand. Indeed, gossypol synergistically
nteracts with Apo2L/TRAIL to induce profound induction
f apoptosis in cultured thoracic cancer cells and, most
mportant, not in primary normal cells. Experiments are also
n progress to elucidate the exact molecular mechanism(s)
y which gossypol interacts with Apo2L/TRAIL to mediate
rofound cytotoxicity in cancer cells.
The recent discovery of small-molecule chemical inhib-
tors of Bcl2/BclXL by virtue of their ability to interact with
he BH3-binding pocket of these proteins has suggested a
ew approach for cancer therapy. These compounds exhibit
trong anticancer activity in many tumor cells, especially in
hose expressing high levels of Bcl2/BclXL.15 They also
otentiate the tumoricidal effects of standard cytotoxic che-
otherapeutics or radiotherapy20,21 as well as of Apo2L/
RAIL, as reported herein by our group or by other inves-
igators.22,23 Gossypol interacts with the BH3-binding
ockets of 4 antiapoptotic proteins, Bcl2, BclXL, BclW, and
fl1, displacing BH3 peptide with an IC50 of about 0.5
mol/L.14 Naturally occurring gossypol exists as a racemic
ixture of () and () enantiomers. Interestingly, the ()
nantiomer of gossypol possesses higher affinity for Bcl2
nd BclXL, reduced serum binding, and greater anticancer
ctivity in in vitro assays than the () enantiomer or race-
ic gossypol.15 Gossypol, a polyphenolic containing two
ldehyde groups, is a highly reactive compound, which may
xplain some of toxicities originally seen in phase 1 clinical
rials of this drug in addition to producing unfavorable
harmacologic properties.14 Structural modification of gos-
The Journal of Thoracicypol by removal of these ahdehyde groups creates apog-
ssypol, a semisynthetic BH3-mimetic drug with a better
harmacologic profile. The () gossypol and apogossypol
re being jointly developed as Bcl2-targeted anticancer
rugs by the National Cancer Institute with Ascenta Ther-
peutics, Inc (San Diego, Calif), and the Burnham Institute
La Jolla, Calif), respectively.14 Evaluation of the therapeu-
ic efficacy and toxicity profile of the ()gossypol Apo2L/
RAIL combination in vitro and in vivo animal model of
ude mice bearing human cancer xenografts is the current
ocus of our laboratory effort to facilitate translation of the
ossypolApo2L/TRAIL drug combination into clinical
pplication. Moreover, our findings form the basis for fur-
her evaluation of this combination strategy using synthetic
ompounds specifically designed as BH3 mimetics such as
H3I-2= or HA14-1 in cultured thoracic cancer cells.
In summary, we report for the first time profound cyto-
oxicity and apoptosis mediated by the gossypolApo2L/
RAIL combination in cultured thoracic cancer cells via
process that is caspase-mediated and dependent on the
itochondria-regulated death signaling pathway. More im-
ortant, this drug combination is not toxic to primary nor-
al cells. Our study, in conjunction with other reports cited
n this manuscript, provides a strong rationale for further
evelopment of Apo2L/TRAIL-based therapy in combina-
ion with BH3 mimetics as novel targeted molecular thera-
eutic for cancers.
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iscussion
r David R. Jones (Charlottesville, Va). I congratulate you on a
ice presentation.
You hypothesized that gossypol would enhance Apo2L and
RAIL-mediated apoptosis through its ability to inhibit Bcl2 and
erhaps BclXL. Do you have any evidence that this is indeed the
athway? For instance, have you performed any siRNA experi-
ents with either Bcl2 or BclXL that would be more confirmatory
f your hypothesis?
Second, gossypol has been shown to increase both Fas and Fas
igand expression, which has been suggested to account for at least
5% of apoptosis in certain non–small cell lung cancer cell lines.
o you think this may be the mechanism through which gossypol
s truly working, and, if not, why not?
Finally, if you believe you can move this preclinical data
oward a phase 1 trial, can you tell us whether there are any
ombined or additive toxicities of these two biologic agents?
Dr Yeow. Thank you, Dr. Jones.
To answer your first question, gossypol inhibiting Bcl2/BclXL,
t has not been shown by us but it has been shown by previous
uthors using colon carcinoma that gossypol does interact as a
H3 mimetic, does bind to the pocket of Bcl2/BclXL. They
howed it through one assay that demonstrates that if two proteins
ome together, there is fluorescence. They were also able to show
t in another one using x-ray crystallography. Thus it has been
hown that gossypol will bind to the pocket.
Second, in terms of gossypol affecting 70% of non–small cell
ung carcinomas and that being the sole agent, we are using a
oncentration of gossypol that does not do that. We are aiming for
uboptimal doses, and we are using suboptimal doses of both
ossypol and TRAIL. We hope that they will combine and selec-
ively target the cancer cells.
Third, the ability to take it to a phase 1 trial, the gossypol that
e are using is a mix of positive and negative enantiomers, and it
s not as potent as the negative enantiomer, which is the agent that
as been taken to clinical trials. There is a better secondary,
ertiary, third generation of gossypol that could potentially be
aken to clinical trials. We do not anticipate gossypol as a mix to
e taken there at that level.
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G
TSigure E1. Gossypol-mediated induction of apoptosis. Cells were
xposed to gossypol (5.0 or 10.0 mol/L) for either 24 hours or 48
ours and harvested at 48 hours after the onset of gossypol
reatment for quantitation of apoptosis using the TUNEL-based
poBrdU assay. Data are presented as means  SEM of 4
ndependent experiments, #P < .001 versus gossypol 5.0 mol/L
48 hours,P< .01 versus gossypol 10.0 mol/L 24 hours, *P
.001 versus gossypol 5.0 mol/L  24 hours. G, Gossypol;
UNEL, terminal deoxynucleotidyltransferase–mediated dUTP
ick-end labeling; micM, micromoles per liter.The Journal of Thoracic anigure E2. The effect of the duration of gossypolApo2L/TRAIL
reatment on gossypol-mediated reduction of Apo2L/TRAIL IC50
alues in representative H211, H460, and TE12 cells. Cells were
reated with gossypolApo2L/TRAIL combination for 12 hours, 24
ours, or 36 hours, and cell viability was quantified by MTT at 36
ours after the onset of Apo2L/TRAIL exposure. Data are pre-
ented as means  SEM of 4 independent experiments; #P 
0061 by ANOVA with statistically significant difference (P < .01)
nly between gossypolApo2L/TRAIL 12 hours and 36 hours; **P
.071 and P  .077 by ANOVA and P > .05 by Bonferroni
airwise analysis. G, Gossypol.d Cardiovascular Surgery ● Volume 132, Number 6 1362.e1
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G
TSigure E4. Abrogation of gossypolApo2L/TRAIL-mediated cyto-
oxicity by Z-VAD-fmk. Cells were treated with 24 hours of gos-
ypol, Apo2L/TRAIL, or gossypolApo2L/TRAIL with or without
rior exposure to Z-VAD-fmk (60 m). Cell viability was deter-
ined by MTT 36 hours after the onset of drug exposure. Data are
resented as means  SEM of 4 independent experiments; #P <
0001, P  .0006 between gossypolApo2L/TRAIL with and
ithout Z-VAD-fmk.igure E3. Supra-additive activation of caspases 9 and 3 specific
roteolytic activity in H460, TE2, and TE12 cells treated with the
ossypolApo2L/TRAIL combination. Cells were treated with
ossypol (5.0 mol/L), Apo2L/TRAIL (10 ng/mL for H460 cells or 20
g/mL for TE2 and TE12 cells), or gossypolApo2L/TRAIL combi-
ation. Representative data of 3 independent experiments are
hown here. G, Gossypol.ecember 2006
